最新消息
News

漢康生技於 BIO-Europe 2026 展現臨床研發成果 推動全球藥廠策略合作新契機 HanchorBio Turns Clinical Progress into Global Pharma Partnering Momentum at BIO-Europe 2026
HanchorBio announced strong global business development momentum following BIO-Europe 2026 in Cologne, Germany.
11 月 19, 2026
Read more
漢康生技於癌症免疫治療學會年會展現巨噬細胞導向免疫療法進展 發表臨床進度與新一代三特異性創新技術 HanchorBio Advances Macrophage-Directed Immunotherapy at SITC 2026, Highlighting Clinical Progress and Next-Generation Trispecific Innovation
HanchorBio highlighted findings from four scientific presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentations demonstrated progress across HanchorBio’s clinical and preclinical pipeline, reinforcing its strategy to advance cancer immunotherapy beyond individual checkpoints through coordinated innate and adaptive immune modulation.
11 月 09, 2026
Read more
漢康生技四篇科學摘要獲 ESMO 2026 年會接受 展現差異化免疫治療研發策略 HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HanchorBio announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
10 月 27, 2026
Read more
漢康-KY於 BIO-Europe 2026 推進 HCB101 全球策略合作機會 HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
HanchorBio announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
10 月 27, 2026
Read more
漢康生技參展BioJapan 2026 深化日本市場拓展並推進全球合作機會 HanchorBio Expands Global Pharma Engagement at BioJapan 2026
HanchorBio announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.
10 月 12, 2026
Read more
漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day
HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
9 月 23, 2026
Read more
漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026
HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).
9 月 18, 2026
Read more
漢康生技將於 BioCon China Expo 2026 分享巨噬細胞增強平台與免疫治療布局 HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026
HanchorBio announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.
9 月 14, 2026
Read more
漢康-KY受邀出席統一證券秋季投資論壇 分享臨床開發、產品布局與全球化策略 HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy
HanchorBio highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.
9 月 08, 2026
Read more
漢康生技 HCB101 與 HCB301 雙獲 KSMO/FACO 2026 肯定 HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301
HanchorBio announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea.
9 月 07, 2026
Read more